EU/3/18/2067

About

On 24 August 2018, orphan designation (EU/3/18/2067) was granted by the European Commission to Omeros London Limited, United Kingdom, for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (also known as OMS721) for treatment in haematopoietic stem cell transplantation.

Key facts

Active substance
Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2
Disease / condition
Treatment in haematopoietic stem cell transplantation
Date of decision
24/08/2018
Outcome
Positive
Orphan decision number
EU/3/18/2067

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Omeros London Limited
2nd Floor, Berkeley Square House
Berkeley Square
London W1J 6BD
United Kingdom
Tel. +44 (0) 20 7887 6296
E-mail: regulatory@omeros.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating